Ibalizumab‐uiyk as a bridge therapy for a patient with drug‐resistant HIV‐1 infection receiving chemotherapy: A case report
- 10 June 2021
- journal article
- case report
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (4) , 1185-1187
Abstract
What is known and objective Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered. Case description A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was started to ensure he was on three active HIV medications. What is new and conclusion Ibalizumab-uiyk has no known drug-drug interactions and may be used as bridge therapy for patients with drug-resistant HIV undergoing chemotherapy.Keywords
This publication has 7 references indexed in Scilit:
- Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 InfectionAntimicrobial Agents and Chemotherapy, 2019
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1New England Journal of Medicine, 2018
- HIV-1 drug resistance and resistance testingInfection, Genetics and Evolution, 2016
- Management of HIV Infection in Patients With Cancer Receiving ChemotherapyClinical Infectious Diseases, 2014
- Malignancies in HIV/AIDSAIDS, 2014
- Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsAIDS, 2013
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentNew England Journal of Medicine, 2006